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Introduction and Background
Chemotherapy is considered the first drug of choice of physicians to treat cancer patients; between 500,000 and 1 million Americans receive chemotherapy each year. Nausea and vomiting affects 70 to 80 percent of people who receive chemotherapy and can result in significant morbidity ( Rudolph. Navari, 2007 ) . First of all the classification of nausea and vomiting in patients receiving chemotherapy could be acute: i.e. occurring within 24 hours of chemotherapy; delayed, occurring between 24 hours and 5 days after treatment; breakthrough, occurring despite prophylactic treatment; anticipatory, occurring before chemotherapy treatment; and refractory, occurring during subsequent cycles when antiemetics have failed in earlier cycles; this effect varies from one patient to another according to chemotherapy type, doses, route and patient experience.
Nausea and vomiting, is considered a large and serious problem affecting patients who receive chemotherapy and affects their quality of life. This needs more focus on the problem and the method to prevent or decrease chemotherapy induced nausea and vomiting (CINV) to improve patient quality of life (QOL).
The main purpose of this review is to analyze the impact of chemotherapy induced nausea and vomiting on quality of life among patients with leukemia.
Methodology
To critically examine the effect of chemotherapy induced nausea and vomiting on quality of life among leukemia patients, a comprehensive literature review was conducted using the electronic databases of nursing, Ovid, Science Direct, the Cumulative Index to Nursing and Allied Health Literature "CINAHL "and Pubmed for articles published Biomedical journals were used to search the electronic databases using keywords: nausea and vomiting, quality of life, leukemia, chemotherapy. Key words were used in multiple combinations to conduct an extensive search of these databases. Computerized listings from nursing Ovid, Science Direct, CINAHL and Pubmed contained, a total of 42 articles that were identified and after exclusion of duplicates, the review utilized 8 articles which met the inclusion criteria.
Article inclusion criteria for the integrative research review were the following:
1. It is a research-based study.
It included a population of patient
cancer more than 18 years.
3. It investigated chemotherapy induced nausea and vomiting.
4. It is written in the English language.
5. Is published in the last 6 years.
Based on the inclusion criteria, a total of 8 articles published from 2006 to 2012 were selected and formed the basis for this review. The earliest study included was published in 2006, with most studies published from 2011 through to 2012. Most articles were published in nursing journals.
Countries within which the studies for this review were conducted, include the United States, Spain, Indonesia, Germany, and England.
Methodological Characteristics:
The eight studies composing this integrative research review were quantitative studies. Jiménezet.al evaluated the incidence and severity of chemotherapyinduced nausea and vomiting (CINV) in oncohematology in routine clinical practice, and its impact on quality of life, with the study including: acute myeloid leukemia and stem cell transplant recipients. One hundred consecutive transplant and 77 acute myeloid leukemia patients were studied. Among patients with emesis, the mean percentage of days with emesis and the mean total o r I g I n a l C o n t r I B u t I o n a n d C l I n I C a l I n V e s t I g a t I o n MIDDLE EAST JOURNAL OF NURSING VOLUME 7 ISSUE 3, JUNE 2013
MIDDLE EAST JOURNAL OF NURSING JULY 2012, VOLUME 6 ISSUE 4 o r I g I n a l C o n t r I B u t I o n a n d C l I n I C a l I n V e s t I g a t I o n MIDDLE EAST JOURNAL OF NURSING VOLUME 3, JUNE 2013 number of emetic episodes were 61% and 9.4 (transplant recipients), and 53.6% and 6.2 (leukemia patients), respectively. CINV control was lower in the delayed than in the acute phase.
Cohen et.al study participants recorded occurrence of CINV by completing a daily diary each day for the first 8 days after treatment during each cycle and the Functional Living Index-Emesis (FLIE) before chemotherapy, at the end of day 1 and day 6 after chemotherapy. Mixed model regression analysis was used to explore the association between occurrence of and its impact on patient QOL and he found occurrence of CINV significantly interfered with patient QOL as assessed by the FLIE.
Enzo Ballatori et al, assessed adult cancer patients who were receiving cisplatin-containing regimens and reported incidence and intensity of CINV for eight consecutive days in a diary and completed a Functional Living Index for Emesis (FLIE) questionnaire.
Conclusion and Recommendation
Although the fact that the effect of CINV on QOL has a short-term effect, its evaluation is useful for clinical decisions concerning the choice of appropriate antiemetic prophylaxis. Only the result of an antiemetic randomized clinical trial can help to reach this goal. Because of the subjectivity of patient's answers, only a double-blind study can be assured to provide reliable results.
Finally, the correct choice of the antiemetic treatments can lead to useful results to improve quality of life. In fact, if new antiemetic prophylaxis were compared to a treatment different from the standard therapy, no information about the differences between the mean scores of the new treatment and standard therapy would be available. The above mentioned difference can lead only to less efficacy of the used comparison with regards to the standard antiemetic therapy. For the same reasons any comparison involving optimal antiemetic regimens could be regarded as useless for a specific clinical decision. Unfortunately not one of the of eight comparative studies identified in our review was randomized and double-blind. Therefore, only the results of two studies can be regarded as helpful for orienting the choice of an antiemetic prophylaxis.
Summarizing the results obtained from the review show that the antiemetic prophylaxis, allowing better control for nausea and vomiting during the first day of chemotherapy, also lead to an improvement in the patients QOL.
Among the 8 comparative studies, heterogeneity of instruments aimed at evaluating QOL was detected: in 3 studies FLIE tools, in 3 the EORTC QLQ-C30, and in 2 (FACT-G) tools. The reasons for the choice of the instrument to use to assess the influence of emesis on QOL are clearly described by Jordan et al.
In conclusion, even if the number of the published studies specifically aimed to evaluate the impact of the chemotherapy-induced emesis on QOL are considered high, those showing results that are reliable and helpful to orient clinical practice are few. Also considering the improvement in antiemetic guidelines, therapy obtained in the last years, and the more frequent implementation of reliable antiemetic guidelines, as well as the recent increasing diffusion of lower emetogenic chemotherapy has improved the situation. Despite the existing literature, several gaps were found in the nurses' understanding of the impact of CINV on QOL. How do nurses effectively improve the QOL after administering chemotherapy? When is the appropriate time for nurses to intervene to decrease the impact of CINV on the QOL. In order to fill the gap in the nurse's body of knowledge, a scientific systematic approach is needed to test nursing interventions that are suitable to improve QOL, in order to achieve that. Further studies are needed to achieve a better understanding about the QOL in patients who suffer from CINV.
